Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2020-06-19 Director's Dealing
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
Director's Dealing 2020
Director's Dealing
2020-06-19 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 11, 2020, reporting a specific event: the granting of stock options to an executive officer, Dr. Mark R. Dybul. The key section is Item 5.02, which relates to the departure or appointment of directors or officers and compensatory arrangements. The content focuses on management changes and compensation, not on financial results, audit, or other report types. The document length is 3425 characters, which is relatively short and consistent with an 8-K filing for management changes. Therefore, the document fits the category of Board/Management Information (MANG).
2020-06-16 English
Director's Dealing 2020
Director's Dealing
2020-06-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 8, 2020, by Enochian Biosciences Inc. It announces the completion of a regulatory advice meeting (INTERACT) related to a product but does not contain financial statements or detailed financial data. The document is relatively short (3556 characters) and primarily serves as a regulatory announcement with an attached press release. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is not a certification or officer attestation. Given the nature of the filing and the content, it best fits the Regulatory Filings (RNS) category, which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-06-08 English
DEF 14A
Proxy Solicitation & Information Statement
2020-05-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2020, by Enochian Biosciences Inc. It announces the issuance of a press release about scientific presentations at a conference. The document is short (3791 characters) and primarily serves as a current report to disclose an event rather than providing detailed financial data or comprehensive reports. It does not contain financial statements or detailed management discussion. The content fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2020-05-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.